FAQ Library

Join Dr. Lonial as he explains how the new International Myeloma Working Group definition of active multiple myeloma will affect clinical practice.

Join Dr. Landgren as he explains how immunotherapeutic agents and monoclonal antibodies fit into the real-world treatment of patients with multiple myeloma.

Join Dr. Giralt as he explains the new recommended baseline workup tests for multiple myeloma.

Dr. Lonial discusses how to determine which patients will benefit the most from treatment with daratumumab and elotuzumab.

Join Dr. Landgren as he discusses the progression from two- to three-drug regimens, the major clinical benefits of both, and the future direction of combination therapy.

Dr. Sagar Lonial discusses the need for SPEP, UPEP, and immunofixation testing in newly diagnosed multiple myeloma patients, in patients undergoing therapy, or in relapsed and refractory patients.

In this Managing Myeloma FAQ, Dr. Sagar Lonial discusses whether BD or KD should be considered a standard of care in relapsed/refractory multiple myeloma.

Join Dr. Giralt as he explains whether or not the new diagnostic criteria for multiple myeloma will cause confusion between risk of progression assessment and risk stratification for active myeloma.

In this Managing Myeloma FAQ, Dr. Sagar Lonial discusses the best indicator of improved outcomes in multiple myeloma: SCR, CR, IFCR, or MCR.

Join Paul Richardson, MD, in this Managing Myeloma FAQ as he describes true myeloma defining events and their impact on clinical practice.